The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synap...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Lynch, Berkley A., Lambeng, Nathalie, Nocka, Karl, Kensel-Hammes, Patricia, Bajjalieh, Sandra M., Matagne, Alain, Fuks, Bruno
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2004
Pynciau:
Biological Sciences
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC470764/
https://ncbi.nlm.nih.gov/pubmed/15210974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0308208101
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg